Novo Nordisk hits out as Dutch agency advises against insurance cover for Wegovy
Novo had last year applied to Dutch authorities for a coverage of the drug under its insurance
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Danish drugmaker Novo Nordisk said it was disappointed with the recommendation to the Netherlands government to not cover its hugely popular weight-loss drug Wegovy under the country’s basic insurance.
The Dutch Health Care Institute said on Tuesday in its advice to the healthcare minister said it was unclear whether the health effects of Wegovy were large enough to weigh up against the costs of the medicine.
The institute said even though Wegovy is effective for losing weight, more research is needed to determine the actual health effects.
“While we are pleased that the Dutch Health Care Institute recognises the necessary role of medications in the fight against obesity as a chronic disease, we are obviously disappointed in their initial decision,” a Novo Nordisk spokesperson said in an email.
With around 4 million people in the Netherlands likely to benefit from Wegovy, the institute said total costs for the government could rise to around 1.3 billion euros ($1.42 billion). Wegovy is not yet for sale in the country, Novo said.
Novo had last year applied to Dutch authorities for a coverage of the drug under its insurance for a limited group of patients.
The institute also flagged concern about the global shortage of the medicine’s main ingredient, semaglutide, which is vital for the treatment of diabetes.
“These shortages emphasize the importance of critically weighing which people have the largest benefit from a medicine,” it said.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments